ArticleJTO clinical and research reports2023

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.

Kaiwen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.